We are live on ! Find out more
BLFS icon

BioLife Solutions

194 hedge funds and large institutions have $1.07B invested in BioLife Solutions in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 79 increasing their positions, 52 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 52

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

3% more funds holding

Funds holding: 188194 (+6)

2.5% more ownership

Funds ownership: 102.45%104.96% (+2.5%)

5% less capital invested

Capital invested by funds: $1.12B → $1.07B (-$50.8M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K

Holders
194
Holders Change
+6
Holders Change %
+3.19%
% of All Funds
2.55%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
33
Increased
79
Reduced
52
Closed
25
Calls
$6K
Puts
$18K
Net Calls
-$12K
Net Calls Change
+$4.09M

BLFS Hedge Fund Activity: Q2 2025 in Review

194 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q2 2025, worth a combined $1.07B — down 4.5% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BLFS positions and 25 closed out — a net gain of 8 holders — while 79 added to existing stakes and 52 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $65.3M. The largest seller was Casdin Capital, cutting an estimated $22.5M.

  • 194 institutional investors held BioLife Solutions (BLFS) as of Q2 2025, up from 188 in Q1 2025.
  • Funds reported $1.07B of BioLife Solutions stock for Q2 2025, down 4.5% quarter-over-quarter.
  • 33 funds opened new BioLife Solutions positions in Q2 2025 and 25 closed out, a net change of +8 holders.
  • The largest BioLife Solutions buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $65.3M added.
  • The largest BioLife Solutions seller in Q2 2025 was Casdin Capital, an estimated $22.5M sold.

Based on aggregated 13F filings for Q2 2025.